Related Experiment Video
Updated: Jul 30, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Neuropsychiatric Systemic Lupus Erythematosus.
1Department of Medicine (Neurology), University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive--Mail Code 7883, San Antonio, TX 78229-3900, USA. brey@uthscsa.edu
Current Treatment Options in Neurology
|November 30, 2000
Summary
Treating neuropsychiatric systemic lupus erythematosus (NPSLE) requires excluding secondary causes and diagnosing specific nervous system issues. Treatment depends on the manifestation and systemic disease activity, guiding symptomatic or aggressive therapies.
Area of Science:
- Neurology
- Rheumatology
- Immunology
Background:
- Neuropsychiatric systemic lupus erythematosus (NPSLE) presents diverse neurological and psychiatric symptoms.
- Differentiating NPSLE manifestations from secondary causes like infection or medication side effects is critical.
Purpose of the Study:
- To outline diagnostic and treatment strategies for NPSLE.
- To emphasize the importance of excluding secondary causes before attributing symptoms to NPSLE.
Main Methods:
- Diagnostic evaluation involves excluding secondary causes, assessing systemic lupus erythematosus (SLE) activity, and using neuroimaging, electroencephalography, cerebrospinal fluid analysis, nerve conduction studies, and serologic tests.
- Systemic disease activity is monitored via complement levels, anti-dsDNA, CBC, and urinalysis.
Main Results:
- Accurate diagnosis of specific NPSLE manifestations guides treatment decisions.
- Symptomatic treatment is suitable for mild NPSLE symptoms without systemic disease flares.
- High-dose glucocorticoids, potentially with cyclophosphamide, are indicated for severe NPSLE manifestations like psychosis or transverse myelopathy.
Conclusions:
- Effective NPSLE management hinges on precise diagnosis and tailored treatment strategies.
- Treatment intensity is dictated by the specific NPSLE manifestation and overall SLE disease activity.
Related Concept Videos
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:07Narcolepsy
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
01:26Encephalitis ll: Pathophysiology
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...